- Home
- CCIF vs ZURA Comparison
CCIF vs ZURA Comparison
Compare CCIF & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- ZURA
- Stock Information
- Founded
- CCIF 2011
- ZURA 2022
- Country
- CCIF United States
- ZURA United States
- Employees
- CCIF N/A
- ZURA N/A
- Industry
- CCIF Finance/Investors Services
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCIF Finance
- ZURA Health Care
- Exchange
- CCIF Nasdaq
- ZURA Nasdaq
- Market Cap
- CCIF 121.4M
- ZURA 137.2M
- IPO Year
- CCIF N/A
- ZURA N/A
- Fundamental
- Price
- CCIF $5.39
- ZURA $3.21
- Analyst Decision
- CCIF
- ZURA Buy
- Analyst Count
- CCIF 0
- ZURA 9
- Target Price
- CCIF N/A
- ZURA $11.00
- AVG Volume (30 Days)
- CCIF 76.9K
- ZURA 4.3M
- Earning Date
- CCIF 01-01-0001
- ZURA 11-06-2025
- Dividend Yield
- CCIF 25.90%
- ZURA N/A
- EPS Growth
- CCIF N/A
- ZURA N/A
- EPS
- CCIF N/A
- ZURA N/A
- Revenue
- CCIF N/A
- ZURA N/A
- Revenue This Year
- CCIF N/A
- ZURA N/A
- Revenue Next Year
- CCIF N/A
- ZURA N/A
- P/E Ratio
- CCIF N/A
- ZURA N/A
- Revenue Growth
- CCIF N/A
- ZURA N/A
- 52 Week Low
- CCIF $7.43
- ZURA $0.97
- 52 Week High
- CCIF $10.16
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- CCIF 38.22
- ZURA 53.99
- Support Level
- CCIF $5.23
- ZURA $2.07
- Resistance Level
- CCIF $5.95
- ZURA $4.58
- Average True Range (ATR)
- CCIF 0.17
- ZURA 0.35
- MACD
- CCIF -0.02
- ZURA -0.02
- Stochastic Oscillator
- CCIF 18.83
- ZURA 46.30
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.